More revelations from the American Diabetes Association's annual meeting in San Diego,
A welcomed finding is a long acting tablet containing insulin has been found in a feasibility study.
Researchers say they have been trying to find a safe and effective oral insulin for years.
They say it has the potential to increase patients taking the drug on a regular basis.
The oral insulin tablet was compared to injected insulin and a study was done on patients with Type 2 diabetes who had never taken any type of insulin.
The results showed both the pill and injectable insulin substantially improved blood glucose levels.
Read about it HERE:
A long-acting, oral insulin tablet has been found to safely improve glycemic control as effectively as the common, injected insulin glargine in people with Type 2 diabetes, according to the study, "Efficacy and Safety of Oral Basal Insulin: Eight-Week Feasibility Study in People with Type 2 Diabetes (T2DM)," presented today at the American Diabetes Association's 77th Scientific Sessions® at the San Diego Convention Center. Safe and effective oral insulin has been a long-sought after treatment option in diabetes research. As an alternative to routine insulin injections, an easy-to-take oral insulin tablet has the potential to increase patients' medication compliance and may facilitate earlier initiation of insulin therapy.
The study evaluated the effectiveness and safety of OI338GT, an oral insulin tablet, by comparing it to injectable insulin glargine. The study included 50 patients with type 2 diabetes, average age of 61 years and who had never taken any type of insulin. The patients had A1C levels ranging from 7 to 10 percent, while on metformin alone or in combination with other oral diabetes medications. The patients were randomized 1:1 to receive a once daily treatment tablet of OI338GT, or an injection of insulin, glargine U100 (IGlar), once daily for a period of eight weeks. The trial was fashioned as a "double-blind, double-dummy" study, meaning that all patients received one injection and one tablet a day, only one of which contained insulin. To enable participants to achieve a fasting plasma glucose in the target range of 80-126 mg/dL, doses of both insulins were gradually increased once weekly on an individualized basis until no additional therapeutic benefit was seen.
The results showed that both the oral insulin tablet and injectable insulin glargine substantially improved blood glucose levels and other efficacy parameters, with no significant differences between the two insulins at eight weeks. Patients' A1C levels at baseline were compared to their levels at the end of treatment, at eight weeks. The patients in the OI338GT group had an average baseline A1C of 8.1, and an average ending A1C of 7.3. Patients in the IGlar group had an average baseline A1C of 8.2, and an average ending A1C of 7.1.
The number of episodes of hypoglycemia (low blood glucose) was limited and similar in both treatment groups, and no severe hypoglycemia occurred. There were seven incidents of treatment-emergent hypoglycemia in six patients in the OI338GT group, and 11 incidents of treatment-emergent hypoglycemia in six patients in the IGlar group. The rate and type of adverse events was similar. No severe adverse events were observed in either treatment group. A total of 68 adverse events were reported in 32 patients (31 adverse events by 15 subjects treated with OI338GT, and 37 adverse events by 17 patients treated with IGlar).
"The results of our feasibility study show for the first time that it's possible to develop, on a small-scale level, therapeutically meaningful insulin in an easy-to-take oral tablet," said study co-author, Karsten Wassermann, PhD, DSc, project vice president of global development at Novo Nordisk A/S. "Oral insulin has long been considered a highly desirable option in diabetes research, potentially freeing patients from continuous injections in favor of an easy-to-take tablet. While these data are highly encouraging, there is a need to optimize the tablet to further increase the insulin bioavailability. Within the scientific community there is an ongoing search for alternative ways to administer insulin so that we can enable diabetes patients to receive insulin without continuously breaking the skin barrier with a needle. The goal is to provide optimal coverage and ease insulin therapy for patients with diabetes, and now, we're one step closer to achieving that vision."
Further development of this particular oral insulin project has been discontinued by Novo Nordisk because the bioavailability is low and, hence, the required overall investments to produce the OI338GT in quantities for wide public use have been assessed to not be commercially viable. Improvement of technologies involved in the product's development is the focus of ongoing research.
To speak with Dr. Wassermann, please contact the Association's media relations team on-site at the San Diego Convention Center on June 9 - 13, by phone at 619-525-6250 or by email at email@example.com.
The American Diabetes Association's 77th Scientific Sessions, to be held June 9-13, 2017, at the San Diego Convention Center, is the world's largest scientific meeting focused on diabetes research, prevention and care. During the five-day meeting, health care professionals have exclusive access to more than 2,500 original research presentations, participate in provocative and engaging exchanges with leading diabetes experts, and can earn Continuing Medical Education (CME) or Continuing Education (CE) credits for educational sessions. The program is grouped into eight interest areas: Acute and Chronic Complications; Behavioral Medicine, Clinical Nutrition, Education and Exercise; Clinical Diabetes/Therapeutics; Epidemiology/Genetics; Immunology/Transplantation; Insulin Action/Molecular Metabolism; Integrated Physiology/Obesity; and Islet Biology/Insulin Secretion. Brenda Montgomery, RN, MSHS, CDE, President of Health Care and Education, will deliver her address on Saturday, June 10, and Alvin C. Powers, MD, President of Medicine and Science, will present his address on Sunday, June 11. Eight abstracts were selected by the Scientific Sessions Meeting Planning Committee to be presented on Tuesday, June 13, in the President's Oral Session. These abstracts represent important research being conducted in the field of diabetes today. In total, the 2017 Scientific Sessions includes 378 abstracts in 49 oral sessions; 2,152 poster presentations including 50 moderated poster discussions; and 360 published-only abstracts. Join the Scientific Sessions conversation on Twitter, #2017ADA.
About the American Diabetes AssociationMore than 29 million Americans have diabetes, and every 23 seconds another person is diagnosed with diabetes. The American Diabetes Association (Association) is the global authority on diabetes and since 1940 has been committed to its mission to prevent and cure diabetes and to improve the lives of all people affected by diabetes. To tackle this global public health crisis, the Association drives discovery in research to treat, manage and prevent all types of diabetes, as well as to search for cures; raises voice to the urgency of the diabetes epidemic; and provides support and advocacy for people living with diabetes, those at risk of developing diabetes and the health care professionals who serve them. For more information, please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit diabetes.org.
Information from both of these sources is available in English and Spanish. Find us on Facebook (American Diabetes Association), Twitter (@AmDiabetesAssn) and Instagram (@AmDiabetesAssn).
Another finding is a drug that lowers blood sugar levels for people with type 2 diabetes has also been revealed to significantly reduce the risk of both cardiovascular and kidney disease.
Researchers say "Type 2 diabetes is growing rapidly all over the world, and we need drugs that not only deal with glucose levels, but also protect the many millions of people from the very real risks of stroke and heart attack."associated with diabetes.
Here is more on that study:
SAN DIEGO, June 12, 2017 /PRNewswire-USNewswire/ -- A drug that lowers blood sugar levels for people with type 2 diabetes has also been revealed to significantly reduce the risk of both cardiovascular and kidney disease.
The study, "The Integrated Results of the CANVAS Program," by The George Institute for Global Health, has major implications for the treatment of type 2 diabetes, which affects around 450 million people worldwide.
The findings, published in the New England Journal of Medicine, found the drug canagliflozin reduced the overall risk of cardiovascular disease by 14 percent and reduced the risk of heart failure hospitalisation by 33 percent. It was also shown to have a significant impact on the progression of renal disease.
Professor Bruce Neal, of The George Institute for Global Health, said the findings, which were presented at the American Diabetes Association Conference in San Diego, were exciting and offered real hope to people suffering from type 2 diabetes. "Coronary heart disease is the biggest killer by far for people with type 2 diabetes. Our findings suggest that not only does canagliflozin significantly reduce the risk of heart disease; it also has many other benefits, too. We found it also reduced blood pressure and led to weight loss.
"Type 2 diabetes is growing rapidly all over the world, and we need drugs that not only deal with glucose levels, but also protect the many millions of people from the very real risks of stroke and heart attack."
The study is particularly important to Australians because approximately 65 percent of all cardiovascular deaths occur in people with diabetes or pre-diabetes, and diabetes is also the leading cause of end-stage kidney disease. It also reinforces the findings from a previous study that also showed a reduced risk of cardiovascular disease associated with blood sugar level lowering drugs.
Co-author Professor Vlado Perkovic, Executive Director of The George Institute Australia, said: "Both patients and physicians should be tremendously reassured by the results. What we have done is show that the earlier results were not just a one-off. This really is a game changer in the treatment of type 2 diabetes. It not only reduces the risk of heart disease, it also provides real protection against kidney decline, which affects many people with diabetes."
Canagliflozin is known as a SGLT2 inhibitor and is a relatively new type of drug that works by blocking the body's reabsorption of sugar or glucose. This results in more glucose being released in urine and a drop in glucose levels. Most other diabetes drugs work by managing insulin levels.
- The risk of hospitalised heart failure fell by 33 percent.
- Patients were 40 percent less likely to suffer serious kidney decline.
- The overall risk of cardiovascular disease fell by 14 percent.
- The study of more than 10,000 patients in 30 countries also found the drug offered protection, not just for people already suffering cardiovascular disease, but for all with Type 2 diabetes.
- However, individuals were twice as likely to suffer from amputations.
Professor Neal said: "We don't know why there was an increased risk of amputation, and further work is needed in this area. But for now we urge caution in prescribing this drug to people at increased risk of suffering amputation."
A further study on the benefits of canagliflozin related to kidney disease will be published later this year.
Photo Credit: PR Newswire